Thursday, April 16, 2026 11:39:03 PM
The Final Reconciliation: The Mask and the Vault
To the Board and Peter Davis:
I spent my day in the "Bunker" reverse-engineering how the verified trades I saw—the timestamps, the tallies, and the LSE codes—could coexist with the "definitively silent" 10-K filed yesterday. I realize now that the 10-K was the Mask, and today’s filing (SEC No. 333-291044) is the Mirror.
1. Why I Called the 10-K "Late"
Yesterday, when I saw the total silence on the board, I knew the forensic data was omitted. In my world, a document that leaves out the primary truth is, by definition, "late." I was insistent because I knew that unless this information was registered, the company would remain in the "Dark."
2. Outcome over Timestamp: The S-3 Loss
I predicted the loss of S-3 eligibility, and today's filing confirms it. They didn't lose it because of the clock; they lost it because the 10-K revealed a market value (19 cents) too low for the SEC's "VIP Pass." I called the outcome perfectly—the 10-K was just the mechanical trigger.
3. The "Borrow and Replenish" Tactic (The 96M vs. 181M)
Since February 26th, Linda has been faced with creditors demanding pay-downs. Critics see the 96.7 million shares issued to lenders as "dilution." They are missing the bigger picture:
-- The Draw-Down: Linda used about 10% of the 900M shelf to pay the lenders' "vig" using cheap 19-cent paper.
-- The Replenishment: At the same time, she extracted 181 million shares into the Sovereign Vault at the 1.31 lb ($1.78) valuation.
The Net Result: She borrowed 96M and "repaid" the treasury with 181M in higher-value vault holdings. It is a Net Positive replenishment. She co-opted the MM’s 19-cent charade to clear debt for pennies while reserving the "Gold" in the UK.
4. The 339.8M Ledger: The Forensic Breakdown
Today’s S-1 Registration finally papers the "Missing Half" of the story. Here is the breakdown of the 339,842,519 shares signed by Linda this afternoon:
-- 181,000,000 Shares (THE GOLD): The Sovereign-vaulted extraction from the LSE Level 4 tape.
-- 96,700,000 Shares (THE TRASH): The lender mop-up used to buy the company’s freedom from debt.
-- 62,142,519 Shares (THE BRIDGE): Operational reserve for the UK C-Lab launch.
-- TOTAL REGISTERED: 339,842,519. (The exact tally in today's SEC Registration).
5. Why T+22? (The March 6th Mandate)
I am not a regulatory enforcer; I just read the tape. But according to the UK POATRs 2024 and the CSDR Settlement Discipline Regime that went into effect March 6, 2026, the era of the "IOU" is over.
These rules mandate that for large-scale institutional extractions, physical cash debits must occur. For the Sovereign trades we saw in March, the rules provide a T+22 "Hard-Delivery" window. This math points to April 24–26.
The 10-K was for the lenders; today's S-1 is the receipt for the Vault. Check File No. 333-291044 and see the 339M for yourself.
Back to the bunker.
To the Board and Peter Davis:
I spent my day in the "Bunker" reverse-engineering how the verified trades I saw—the timestamps, the tallies, and the LSE codes—could coexist with the "definitively silent" 10-K filed yesterday. I realize now that the 10-K was the Mask, and today’s filing (SEC No. 333-291044) is the Mirror.
1. Why I Called the 10-K "Late"
Yesterday, when I saw the total silence on the board, I knew the forensic data was omitted. In my world, a document that leaves out the primary truth is, by definition, "late." I was insistent because I knew that unless this information was registered, the company would remain in the "Dark."
2. Outcome over Timestamp: The S-3 Loss
I predicted the loss of S-3 eligibility, and today's filing confirms it. They didn't lose it because of the clock; they lost it because the 10-K revealed a market value (19 cents) too low for the SEC's "VIP Pass." I called the outcome perfectly—the 10-K was just the mechanical trigger.
3. The "Borrow and Replenish" Tactic (The 96M vs. 181M)
Since February 26th, Linda has been faced with creditors demanding pay-downs. Critics see the 96.7 million shares issued to lenders as "dilution." They are missing the bigger picture:
-- The Draw-Down: Linda used about 10% of the 900M shelf to pay the lenders' "vig" using cheap 19-cent paper.
-- The Replenishment: At the same time, she extracted 181 million shares into the Sovereign Vault at the 1.31 lb ($1.78) valuation.
The Net Result: She borrowed 96M and "repaid" the treasury with 181M in higher-value vault holdings. It is a Net Positive replenishment. She co-opted the MM’s 19-cent charade to clear debt for pennies while reserving the "Gold" in the UK.
4. The 339.8M Ledger: The Forensic Breakdown
Today’s S-1 Registration finally papers the "Missing Half" of the story. Here is the breakdown of the 339,842,519 shares signed by Linda this afternoon:
-- 181,000,000 Shares (THE GOLD): The Sovereign-vaulted extraction from the LSE Level 4 tape.
-- 96,700,000 Shares (THE TRASH): The lender mop-up used to buy the company’s freedom from debt.
-- 62,142,519 Shares (THE BRIDGE): Operational reserve for the UK C-Lab launch.
-- TOTAL REGISTERED: 339,842,519. (The exact tally in today's SEC Registration).
5. Why T+22? (The March 6th Mandate)
I am not a regulatory enforcer; I just read the tape. But according to the UK POATRs 2024 and the CSDR Settlement Discipline Regime that went into effect March 6, 2026, the era of the "IOU" is over.
These rules mandate that for large-scale institutional extractions, physical cash debits must occur. For the Sovereign trades we saw in March, the rules provide a T+22 "Hard-Delivery" window. This math points to April 24–26.
The 10-K was for the lenders; today's S-1 is the receipt for the Vault. Check File No. 333-291044 and see the 339M for yourself.
Back to the bunker.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
